Meeting
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
Authors
Saveri Bhattacharya
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Saveri Bhattacharya , Cindy Yun , Katja Schulze , Tullia C. Bruno , Brenda F Kurland , Mark A. Socinski , Liza Cosca Villaruz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03014648
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9105)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9105
Abstract #
TPS9105
Poster Bd #
426b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
First Author: Nikhil Shukla
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
First Author: Jeddeo Paul
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih